Deutsche Bank Ag\ Summit Therapeutics Inc. Transaction History
Deutsche Bank Ag\
- $218 Billion
- Q2 2024
A detailed history of Deutsche Bank Ag\ transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 47,693 shares of SMMT stock, worth $958,629. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,693
Previous 71,526
33.32%
Holding current value
$958,629
Previous $296,000
25.68%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SMMT
# of Institutions
138Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$467 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$177 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$82.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$59.6 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.04B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...